Fuhong Hanlin (02696): The international multicenter phase 2 clinical study of injection HLX43 (PD-L1 targeted antibody conjugate drug) for the treatment of advanced non-small cell lung cancer has been completed with the first patient dosed in Australia.

Zhixin Finance APP News, Fosun Pharma (02696) announced that a phase 2 clinical study of injection drug HLX43 (a PD-L1 targeting antibody-drug conjugate) in late-stage non-small cell lung cancer (NSCLC) patients has completed dosing for the first patient in Australia. This phase 2 clinical study is also being conducted simultaneously in China (excluding Hong Kong, Macao, and Taiwan) and the United States.